Clinical Trials and Research Studies
Phase 3
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized Double-blind Phase 3 Study (KEYNOTE 716)
Learn MorePhase 1/2
A Phase 1/2 Open-Label Dose-Escalation Safety and Tolerability Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors
Learn MorePhase 2
A randomized open-label phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma
Learn MorePhase 1/2
First In Human open-label dose-escalating trial with expansion cohorts to evaluate safety of Axl specific antibody drug conjugate (HuMax -AXL-ADC) in patients with solid tumors
Learn More